Document 1033
 DOCN  M94A1033
 TI    Effects of enteral nutrition supplements on HIV disease.
 DT    9412
 AU    Cope FO; Hellerstein M; University of California, San Francisco.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):224 (abstract no. PB0910). Unique
       Identifier : AIDSLINE ICA10/94371542
 AB    A doubleblind, prospective, randomized trial evaluated the effects of
       enteral nutrition supplementation on nutrient intake, body composition,
       GI symptoms, nutritional status and AIDS specific surrogate markers in
       subjects with AIDS or HIV-associated weight loss (13.2 +/- 4.2% body
       wt). A whole protein (WP) and a peptide-based (PB) formula were
       administered over 1 yr with evaluations at 6 weeks, 6 months and 12
       months. Subjects ingested up to two 8 oz cans/day. Both formulas were
       well-tolerated and there were no adverse effects on GI function or
       related symptoms. Evaluation of food and formula intake at 6 months
       revealed an increased intake of calories and protein in both groups.
       This occurred through supplement intake (500-600 kcal/day and 17-28g
       protein/day) which resulted in some decrease in spontaneous food intake
       (196-382 kcal/day and 5.6-14.45 protein/day). The net increase was
       approximately 400 kcal/day. REE was elevated compared to normals (110%
       predicted) at baseline & did not change during supplementation. The
       response of fat free mass (FFM) at 6 wks was significantly correlated
       (r2 = -0.42, p < 0.01) with baseline hepatic fat synthesis (an index of
       cytokine presence and metabolic dysregulation). A majority of patients
       maintained their entrance body weight as only 20% experienced reductions
       of 2.2 kg or greater. When considering all data from the 1 yr followup,
       the risk of a > or = 50% drop from baseline in the CD4 count was 7.4
       times greater in the WP than the PB group (p < 0.01). In conclusion,
       total intake of nutrients increased even after reduction of voluntary
       food intake was considered. This increased macro and micro nutrient
       intake resulted in apparent weight maintenance without untoward GI
       symptom or function. Specific dietary management with the PB formula may
       provide added clinical benefit based on the CD4 analyses.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS/*THERAPY
       Cachexia/ETIOLOGY/*THERAPY  Caloric Intake/DRUG EFFECTS  Double-Blind
       Method  *Enteral Nutrition  Human  Nutritional Status/DRUG EFFECTS
       Prospective Studies  CLINICAL TRIAL  MEETING ABSTRACT  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).